Myocardial Diseases
Özet
Regardless of the frequency, almost all rheumatological diseases show varying degrees of cardiac involvement. Primary or secondary cardiac effects of rheumatological diseases may occur with specific or nonspecific symptoms due to involvement in the pericardium, myocardium, valves, conduction system, coronary arteries, or may manifest itself as pulmonary hypertension with pulmonary vascular effects. Although cardiac involvement and symptoms occur mostly in the late period, the fact that cardiac involvement is the most important factor determining mortality in rheumatic diseases reveals the importance of early diagnosis. In this section, cardiac interactions of relatively common rheumatologic diseases such as Rheumatoid arthritis, Systemic lupus erythematosus, Systemic sclerosis, vasculitis, Behçet's disease, Sjögren syndrome, Ankylosing spondylitis and Inflammatory myopathies will be discussed.
Referanslar
Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7.
Cathcart ES, Spodick DH. Rheumatoid heart disease: a study of the incidence and nature of cardiac lesions in rheumatoid arthritis. N Engl J Med. 1962 May;266:959-964.
Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006, 54, 60–67.
Giles JT, Fernandes V, Lima JA, et al. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther. 2005, 7:195-207.
Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36–40.
Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46:1714–1719.
Cioffi G, Viapiana O, Ognibeni F, et al. Combined circumferential and longitudinal left ventricular systolic dysfunction in patients with rheumatoid arthritis without overt cardiac disease. J Am Soc Echocardiogr. 2016;29:689–98.
Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a populationbased study over 46 years. Arthritis Rheum. 2005;52:412–20.
Mantel A, Holmqvist M, Andersson DC, et al. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. Journal of the American College of Cardiology. 2017;69(10):1275-1285. doi:10.1016/j.jacc.2016.12.033.
Davis JM, Roger VL, Crowson CS, et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 2008;58(9):2603-2611. doi:10.1002/art.23798.
Torre-Amione G. Kapadia S, Lee J. et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996; 93(4), 704-711.
Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA. 2000;97:12746–12751.
Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002;61:1065–70
Law WG, Thong BY, Lian TY, et al. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14:827–31.
Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14:683–6.
Lee SS, Singh S, Link K, et al. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum. 2008;38:41–54.
Mavrogeni SI, Kitas GD, Dimitroulas T, et al. Cardiovascular magnetic resonance in rheumatology: current status and recommendations for use. Int J Cardiol. 2016;217:135–48.
Muangchan C, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013;40:1545–56.
Gargani L, Todiere G, Guiducci S, et al. Early detection of cardiac involvement in systemic sclerosis: the added value of magnetic resonance imaging. JACC Cardiovasc Imaging. 2019;12(5):927–8.
Moroncini G, Schicchi N, Pomponio G, et al. Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. Radiol Med. 2014;119:885–94.
Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol. 2010;28:S48–53.
Tennoe AH, Murbraech K, Andreassen JC, et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. J Am Coll Cardiol. 2018;72:1804– 1813. doi: 10.1016/j.jacc.2018.07.068.
Hinchcliff M, Desai CS, Varga J, et al. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol. 2012;30:S30–S37.
Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131–7.
Pugnet G, Sailler L, Fournier JP, et al. Predictors of cardiovascular hospitalization in giant cell arteritis: effect of statin exposure. A French population-based study. J Rheumatol. 2016;43:2162–70.
Simon R, Perel-Winkler A, Bokhari S, et al.. Myocarditis in giant cell arteritis diagnosed with fluorine 18-labeled fluorodeoxyglucose positron emission tomography-computed tomography: case report and review of the literature. J Clin Rheumatol. 2020;26: e37–e40, doi: 10.1097/RHU.0000000000000796.
Comarmond C, Cluzel P, Toledano D, et al. Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis. Am J Cardiol. 2014;113:881–7.
Pellegrin MC, Taddio A, Lepore L. Acute cardiac valvular involvement in Kawasaki disease. Clin Exp Rheumatol. 2011;29:S140.
Polizzotto MN, Gibbs SD, Beswick W, et al. Cardiac involvement in HenochSchonlein purpura. Intern Med J. 2006;36:328–31.
Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91:25–34.
Svealv BG, Tang MS, Klingberg E, et al. Prevalence of diastolic dysfunction in patients with ankylosing spondylitis: a cross-sectional study. Scand J Rheumatol. 2015;44:111–7.
Gonzales Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol. 1996;14: 373–9.
